MEDICAL NEWS SITES

The ASCO Post

Disease-Free Survival in Early-Stage EGFR-Positive NSCLC Improved by Adjuvant Osimertinib - The ASCO Post


Compared with placebo, adjuvant osimertinib significantly improved disease-free survival in patients with stage IB to IIIA EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. Reported during the Plenary Program of the ASCO20 Virtual Scientific Program, these findings are from the first interim analysis of the phase III ADAURA trial.1 In patients with stage II to IIIA NSCLC, osimertinib improved disease-free survival by 83% vs placebo (P < .0001).


Read more

dt_200707_lung_cancer_ct_800x450.jpg

MedScape

Radiomics Can Identify High-Risk Early Stage Lung Cancer


Radiomics, a growing area of cancer research that extracts noninvasive biomarkers from medical imaging, may be able to improve lung cancer screening by identifying patients with early stage disease at high risk for poorer outcomes. This is the conclusion from a group of researchers who used data from the National Lung Screening Trial (NLST) to develop and validate a model based on radiomics that could identify a vulnerable high-risk group of early stage patients associated with poor outcomes. These patients would generally require aggressive follow-up and/or adjuvant therapy. The study was published June 29 in Nature Scientific Reports. Radiomics, also known as quantitative image features, are noninvasive biomarkers that are generated fr...


Read more

87444.jpg

MedPageToday

USPSTF: Extend Eligibility for CT Lung Cancer Screening


Proposed national recommendations would nearly double the number of smokers and former smokers in the U.S. who are eligible for annual low-dose CT (LDCT) lung cancer screening. The U.S. Preventive Services Task Force (USPSTF) issued a draft recommendation statement Tuesday that annual LDCT screening be extended to current smokers between the ages of 50 and 80, who have a 20-pack-year smoking history, and former smokers with the same pack-year history who have quit within the past 15 years (Grade "B" evidence). LDCT screening is not recommended for people who have not smoked for the past 15 years and those with health problems that limit life expectancy or their eligibility for curative lung cancer surgery. The proposed recommendation low...


Read more

OncLive

Lung Cancer | OncLive


Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.


Read more

The ASCO Post

First-Line Nivolumab Plus Ipilimumab Shows Activity in NSCLC, With or Without Chemotherapy - The ASCO Post


Advanced non–small cell lung cancer (NSCLC) in patients whose tumors have no EGFR or ALK alterations poses a particular challenge in terms of first-line therapy. The use of nivolumab plus ipilimumab as well as nivolumab/ipilimumab plus two cycles of chemotherapy, respectively, as first-line therapy for advanced NSCLC is supported by two different trials, CheckMate 227 and CheckMate 9LA. These study results were presented at the ASCO20 Virtual Scientific Program. Updated follow-up of CheckMate 227 at 3 years showed that nivolumab plus ipilimu­mab extended overall survival compared with chemotherapy alone in patients with PD-L1–positive (ie, ≥ 1%) tumors.


Read more

The ASCO Post

Issues - The ASCO Post


Issues 2020 July 10, 2020 - Supplement: Conference Highlights ASCO20 Virtual Scientific Program June 25, 2020 June 10, 2020 June 3, 2020 - Narratives Special Issue May 25, 2020 May 10, 2020 April 25, 2020 April 10, 2020 March 25, 2020 March 25, 2020 - Supplement: Conference Highlights GI Cancers March 10, 2020 March 10, 2020 - Supplement: Conference Highlights SABCS 2019 February 25, 2020 February 25, 2020 - Supplement: Conference Highlights ASH 2019 February 10, 2020 January 25, 2020 2019 December 25, 2019 December 10, 2019 November 25, 2019 November 10, 2019 – Supplement: ESMO Highlights November 10, 2019 October 25, 2019 October 10, 2019 September 25, 2019 September 10, 2019 August 25, 2019 August 1...


Read more

The ASCO Post

July 10, 2020 - Supplement: Conference Highlights ASCO20 Virtual Scientific Program - The ASCO Post


Compared with placebo, adjuvant osimertinib significantly improved disease-free survival in patients with stage IB to IIIA EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. Reported during the Plenary Program of ... According to an interim analysis of the phase III JAVELIN Bladder 100 trial, rates of survival among patients with advanced urothelial carcinoma who did not progress on first-line platinum-based chemotherapy were significantly prolonged by maintenance therapy with avelumab and best supportive care... Rates of Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer Doubled by Pembrolizumab Upfront treatment with immunotherapy no...


Read more

The ASCO Post

EPOV Scott Gettinger - The ASCO Post


Discussant for the CheckMate 227 and CheckMate 9LA trials, Scott N. Gettinger, MD, of Yale Cancer Center in New Haven, Connecticut, said: “There is tremendous interest in lung cancer to combine nivolumab plus ipilimumab, driven by the melanoma experience. However, combinations of immunotherapy come with more toxicity.” Regarding the recent U.S. Food and Drug Administration (FDA) approval of nivolumab plus ipilimumab for patients with PD-L1 ≥ 1% expression, Dr. Gettinger said: “This combination is a new first-line option for PD-L1–expressing NSCLC [non–small cell lung cancer].” The question is whether this is an option for PD-L1–negative NSCLC.


Read more

image.jpg

The ASCO Post

Search Results - The ASCO Post


Your search for all items matches 22669 pages Showing 1 - 50 Advertisement   By The ASCO Post Staff  / July 2020  / ESMO World Congress on Gastrointestinal Cancer 2020 the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor infigratinib resulted in a progression-free survival and... By The ASCO Post Staff  / July 10, 2020 - Supplement: Conference Highlights ASCO20 Virtual Scientific Program  / AS...


Read more

The ASCO Post

Conference Highlights From the ASCO20 Virtual Scientific Program - The ASCO Post


The global outbreak of the COVID-19 pandemic forced many cancer societies, including ASCO, to cancel their in-person meetings this year and instead present the latest advancements and new approaches in oncology care via a virtual platform. For the first time in its 56-year history, the ASCO Annual Meeting was presented entirely virtually. Despite the novel format, the meeting was a success, with the diversity of the program and the extraordinary number of new research presented perfectly captured the theme of this year’s meeting “Unite & Conquer: Accelerating Progress Together.” Throughout this special Conference Highlights issue of The ASCO Post, you’ll find reports from additional clinical trials presented during the virtual program, inc...


Read more

BioSpace

BerGenBio to Present at Digital Novel Coronavirus Investment Forum


BERGEN, Norway, July 7, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that Dr. Akil Jackson, Medical Director at BerGenBio, will be participating at the Sachs Associates Digital Novel Coronavirus Investment Forum on 8-9 July 2020. Dr. Jackson will participate in a panel discussion entitled: The Potential Therapeutic Strategies to Prevent and Conquer Covid-19, on 8 July at 4:15pm CEST.


Read more

BioSpace

New Paper Documents Effectiveness Of Natural Physiological Salts As New Hygienic Intervention To Reduce The Exhalation Of Particles That Transmit Airborne Infectious Disease


CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ -- Today, Sensory Cloud, a technology startup that designs solutions to problems of human well-being and healthcare through pioneering discoveries at the frontiers of olfaction and respiratory biology, announced the publication of a new peer-reviewed paper in QRB Discovery, an interdisciplinary medical journal of biological function, structure and mechanism. The paper establishes the foundation for understanding the hygienic properties of unique combinations of physiological salts, and particularly the ability of these salts to substantially mitigate expiration of the very small particles humans exhale during natural breathing and that are not captured by conventional masks. "Airborne infecti...


Read more

LUNGevity_Foundation_Logo.jpg

BioSpace

Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing


WASHINGTON, July 7, 2020 /PRNewswire/ -- A LUNGevity Foundation-led consortium of 41 leading patient advocacy organizations, professional societies, and industry partners has published a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially lifesaving testing options available for both new cancer diagnoses and progression or recurrence of disease. Research shows that despite widespread acceptance of the importance of testing, actual testing rates lag far behind best-practice recommendations for both biomarker testing for s...


Read more

NCCN_Logo.jpg

BioSpace

JNCCN Study Explores if Insurance is Keeping Pace with Trends in Targeted Cancer Therapy


PLYMOUTH MEETING, Pa., July 7, 2020 /PRNewswire/ -- New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or "liquid biopsies." CtDNA is formed when tumor cells shed cell-free DNA fragments containing valuable information for detecting the tumor's genetic attributes into the bloodstream.


Read more

;w=600;h=315

BioSpace

Director, Safety Scientist: 2020-112 job with Mirati Therapeutics | 2147066


(NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnology company dedicated to advancing novel therapeutics that extend the lives of patients by directly addressing the genetic and immunological drivers of cancer. Mirati is developing sitravatinib, designed to selectively target a spectrum of tyrosine kinases implicated in both tumor growth and the suppression of immune responses to tumors. Sitravatinib has demonstrated durable responses in lung cancer patients whose cancer has progressed despite treatment with checkpoint inhibitors - an area of significant unmet medical need.


Read more

prostate_cancer_foundation_logo.jpg

BioSpace

The Prostate Cancer Foundation Collaboration With Pan-Cancer Consortium Clarifies And Promotes Consistent Use Of Common Terms For Biomarker And Germline Genetic Testing


LOS ANGELES, July 7, 2020 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially life-saving testing options available for both new cancer diagnoses and progression or recurrence of disease.


Read more

BioSpace

A Breakthrough in Cancer Treatment: Soundny Presents a New Drug-based Alternative in Fight Against Cancer


WUHAN, China, July 7, 2020 /PRNewswire/ -- Hubei Soundny Biotechnology ("Soundny" or the "Company"), a leading biotechnology company dedicated to developing cancer treatments, has announced the publication of its latest findings on cholangiocarcinoma in Nature Biomedical Engineering, a Nature publication. The research highlights a drug-loaded microvesicles tumor therapy for cholangiocarcinoma, approved for clinical use which has shown significant efficacy and safety in the treatment of cholangiocarcinoma. Data shows that the United States sees about 10,000 new cholangiocarcinoma cases annually, while the incidence rate in Asia is about 3 in 10,000.


Read more

BioSpace

Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19


Approach stimulates immune response by activating B cells to enhance antibody production Safety and scientific basis supported by ongoing cancer clinical trial Study designed to evaluate anti-viral antibody response in up to 30 COVID-19 patients with mild to moderate symptoms Company to host conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT BURLINGAME, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.


Read more

BioSpace

Stephen Squinto, Ph.D., Named Vice Chairman of bioAffinity Technologies


SAN ANTONIO--( BUSINESS WIRE)-- bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced that Stephen Squinto, Ph.D., has been named Vice Chairman of the Company’s Board of Directors, and David Elzi, Ph.D., has been appointed Vice President of Research in recognition of Dr. Elzi’s pivotal role in the Company’s scientific discoveries related to cancer therapeutics. Dr. Squinto is an Executive Partner with OrbiMed Healthcare Fund Management. He previously co-founded Alexion Pharmaceuticals, Inc., a global biopharmaceutical company focused on the development and commercialization of breakthrough therapies for patients with rare and ultra-rare diseases.


Read more

VIDA_Diagnostics_Todd_Johnson.jpg

BioSpace

Respiratory health AI trailblazer VIDA poised for increased scale with newest appointment to leadership team


CORALVILLE, Iowa, July 7, 2020 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced today that Todd Johnson has joined the company as chief technology officer. Johnson, a leader in enterprise imaging and advanced clinical applications, will apply his expertise to extend the breadth and depth of VIDA's LungPrint® solutions, ensuring the company's AI (artificial intelligence) insights are accessible to a broader base of clinicians to improve the diagnosis and treatment of lung disease.


Read more

The ASCO Post

EPOV Axel Grothey - The ASCO Post


Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in [microsatellite instability-high (MSI-H)] colorectal cancer, a subtype where we know immunotherapy works, from later-line studies. Regulatory bodies have wanted to see a randomized trial comparing immunotherapy to standard-of-care treatment before approving these agents in the first-line setting,” he noted. The findings are not unexpected, based on previous studies in later treatment lines, and they are indeed “very positive,” showing a “dramatic” 40% reduc...


Read more

NEWS SITES

WireAP_71f6db9abbb34ccbbcc10a348d8a78cc_16x9_992.jpg

ABC News

Health panel may open lung cancer screening to more smokers


A U.S. health panel wants to widen the number of current and former smokers offered yearly scans for lung cancer By LAURAN NEERGAARD AP Medical Writer July 7, 2020, 3:02 PM 3 min read A U.S. health panel wants to widen the number of Americans offered yearly scans for lung cancer by opening the screening to less-heavy smokers. Lung cancer is the nation's top cancer killer, causing more than 135,000 deaths each year. Smoking is the chief cause and quitting the best protection. Usually, lung cancer is diagnosed too late for a good chance at survival.


Read more

?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F81%2F3a%2Faddd7e5459e56e756bc056e27e1a%2Fla-xpm-photo-2013-mar-29-la-me-ln-smokers-health-insurance-20130329

LA Times

Twice as many U.S. smokers should be screened for lung cancer, expert panel says


A U.S. health panel wants to increase the number of Americans offered yearly scans for lung cancer by opening the screening to those who smoke less heavily. Lung cancer is the nation's top cancer killer, causing more than 135,000 deaths each year. Smoking is the chief cause and quitting the best protection. Usually, lung cancer is diagnosed too late for a good chance at survival. But research shows that annual low-dose CT scans, a type of X-ray, can reduce the risk of death when offered to certain people.


Read more

200707-lung-ct-scan-se-1056a_90ef2c7c4cc82a0755d392a949bb4e50.nbcnews-fp-1200-630.jpg

NBC News

New guidelines would nearly double lung cancer screenings, benefit more women and Black people


Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings. New recommendations for lung cancer screening would nearly double the number of Americans eligible for the test, according to guidelines released Tuesday by the U.S. Preventive Services Task Force. The draft guidelines propose lowering the eligibility age for lung cancer screening to 50 from 55, and lowering the number of years a person smoked an average of a pack a day (known as “pack years”) to 20 from 30 to qualify for the test. The new recommendations will likely result in more women and African Americans becoming eligible for screenings, the guidelines say. The shift in smoking history to 20 pack years will particularly benef...


Read more

defaultPromoCrop.png

New York Times

Health Panel May Open Lung Cancer Screening to More Smokers


A U.S. health panel wants to widen the number of Americans offered yearly scans for lung cancer by opening the screening to less-heavy smokers. Lung cancer is the nation's top cancer killer, causing more than 135,000 deaths each year. Smoking is the chief cause and quitting the best protection. Usually, lung cancer is diagnosed too late for a good chance at survival. But research shows that annual low-dose CT scans, a type of X-ray, can reduce the risk of death when offered to certain people. In 2013, the U.S.


Read more

JOURNALS

favicon.ico

Dove Press

Circular RNA Circ_0016760 Modulates Non-Small-Cell Lung Cancer Growth | CMAR


Yanhong Hao,1,* Junfeng Xi,1,* Yancai Peng,1 Burong Bian,2 Guangjun Hao,2 Yunfeng Xi,3 Zhibin Zhang1 1Department of Cardiothoracic Surgery, The First Hospital of Yulin, Yulin City, Shanxi Province, People’s Republic of China; 2Department of Oncology, The First Hospital of Yulin, Yulin City, Shanxi Province, People’s Republic of China; 3Department of Dermatological Surgery, The First Hospital of Yulin, Yulin City, Shanxi Province, People’s Republic of China *These authors contributed equally to this work Correspondence: Zhibin Zhang Email r7mj90@163.com Background: Patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) have a poor prognosis.


Read more

gr1.jpg

Lung Cancer

Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non-small cell lung cancer after curative-intent surgery


The impact of sarcopenia on the outcome in patients following resection of non-small cell lung cancer is yet to be fully determined. This study aimed to evaluate the clinical utility of a computed tomography-based pectoralis muscle assessment, which reflects sarcopenia, to predict the risk of postoperative outcomes. This retrospective study included 347 consecutive patients undergoing curative-intent resection of non-small cell lung cancer from 2009 to 2013. The pectoralis muscle index (pectoralis muscle area/body mass index) was assessed at the level of the fourth thoracic vertebra on chest axial images.


Read more

favicon.ico

Dove Press

GINS2 Functions as a Key Gene in Lung Adenocarcinoma by WGCNA Co-Expre


Lung cancer is one of the most prevalent cancers in the world, with 226,160 new cases and 160,340 mortalities in 2012.1 Lung adenocarcinoma is a major subtype of lung cancer.2 Due to the complex pathomechanism, the survival rate of lung adenocarcinoma is still low.3 Therefore, it is important to explore the underlying molecular mechanisms for lung adenocarcinoma development and progression. GINS complex subunit 2 (GINS2), a member of GINS family, plays a crucial role in DNA duplication.4 In acute promyelocytic leukemia, up-regulation of GINS2 facilitated HL60 cell proliferation.5 Down-regulation of GINS2 inhibited breast cancer cells growth by activation of endogenous DNA damage.6,7 Elsewhere, it was found that deregulated GINS2 expression...


Read more

11356.jpg

Springer

Radiation-related health hazards to uranium miners


Abbasi A (2017) Modeling of lung cancer risk due to radon exhalation of granite stone in dwelling houses. J Cancer Res Ther 13(2):208–212 CAS  Google Scholar  Archer VE, Magnuson HJ, Holaday DA, Lawrence PA (1962) Hazards to health in uranium mining and milling. J Occup Med 4:55–60 CAS  Google Scholar  Asic A, Kurtovic-Kozaric A, Besic L, Mehinovic L, Hasic A, Kozaric M, Hukic M, Marjanovic D (2017) Chemical toxicity and radioactivity of depleted uranium: the evidence from in vivo and in vitro studies.


Read more

41577_2020_388_Figa_HTML.jpg

Nature

Driving CARs to clear senescent cells


The accumulation of senescent cells promotes inflammation and chronic tissue damage, thereby contributing to several ageing-associated diseases. Writing in Nature, Lowe, Sadelain and colleagues now report the development of chimeric antigen receptor (CAR) T cells that can selectively and safely target and eliminate senescent cells in mouse disease models, reversing pathology and extending survival. Previous studies have demonstrated that eliminating senescent cells from damaged tissues reduces symptoms and increases lifespan in mouse models of ageing-associated diseases such as cancer, fibrosis, atherosclerosis and osteoarthritis.


Read more

41568_2020_275_Fig1_HTML.png

Nature

In vivo functional screening for systems-level integrative cancer genomics


1.Ding, L. et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 173, 305–320.e10 (2018). CAS  PubMed  PubMed Central  Google Scholar  2.Nangalia, J. Campbell, P. J. Genome sequencing during a patient’s journey through cancer. N. Engl. J. Med. 381, 2145–2156 (2019). CAS  PubMed  Google Scholar  3.Schneider, G., Schmidt-Supprian, M., Rad, R. Saur, D. Tissue-specific tumorigenesis: context matters.


Read more

41571_2020_399_Fig1_HTML.png

Nature

Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm


Robert, C., Schadendorf, D., Messina, M., Hodi, F. S. & O’Day, S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin. Cancer Res. 19, 2232–2239 (2013). European Medicines Agency. Yervoy (ipilimumab). An overview of Yervoy and why it is authorised in the EU. (2011). McCoach, C. E. et al. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.


Read more

41598_2020_68093_Fig1_HTML.png

Nature

Mechanism of Astragalus membranaceus in the treatment of laryngeal cancer based on gene co-expression network and molecular docking


The GSE27020 data set contains a total of 109 laryngeal cancer samples. After removing the genes with too many missing values from samples, an expression matrix containing 13,512 genes was generated. The 3,378 genes with the top 25% of the variance (that is, the genes that change significantly in each sample) are selected for subsequent operations. Clinical phenotypic data included survival time, recurrence, age, and tumor stage. As shown in Fig. S1A. According to the distance of sample clustering, the outliers GSM665579, GSM665597, and GSM665566 were eliminated.


Read more

41416_2020_972_Fig1_HTML.png

Nature

Systematic analysis reveals a functional role for STAMBPL1 in the epithelial–mesenchymal transition process across multiple carcinomas


Deubiquitinating enzymes (DUBs) are linked to cancer progression and dissemination, yet less is known about their regulation and impact on epithelial–mesenchymal transition (EMT). An integrative translational approach combining systematic computational analyses of The Cancer Genome Atlas cancer cohorts with CRISPR genetics, biochemistry and immunohistochemistry methodologies to identify and assess the role of human DUBs in EMT. We identify a previously undiscovered biological function of STAM-binding protein like 1 (STAMBPL1) deubiquitinase in the EMT process in lung and breast carcinomas.


Read more

41598_2020_68168_Fig1_HTML.jpg

Nature

Relationship between radiation doses to heart substructures and radiation pneumonitis in patients with thymic epithelial tumors


In the present study on 70 TET patients treated with RT, the univariate analysis revealed that some dosimetric parameters of the lung and heart substructures correlated with the development of RP, and the percentage of PA volume receiving at least 35 Gy (i.e. PA V35) showed the strongest correlation in the multivariate analysis. PA V35 was higher in the RP group than in the non-RP group (84.2% vs 60.0%, p = 0.003). This result suggests that the moderate dose sparing of PA minimizes the risk of RP in mediastinal RT, and may be applied to thoracic RT in LANSCLC patients. A summary of studies that reported relationships between dosimetric parameters and RP after thoracic RT is shown in Table 41,11,13,14,19,20,21,22.


Read more

d41586-020-01262-3_17930908.jpg

Nature

Cells edited with CRISPR prove safe in humans


People with cancer show no serious side effects after treatment with gene-edited immune cells. The first human trial of cells modified with CRISPR gene-editing technology shows that the treatment is safe and lasting. A team led by You Lu at the West China Hospital in Chengdu took immune cells from people with aggressive lung cancer and applied CRISPR to them to disable a gene called PD-1. Usually, the PD-1 protein sends signals that keep immune cells from mounting an attack against the body’s own tissues, but active PD-1 can open the door to the spread of cancer. The team injected each study participant with edited versions of their own immune cells.


Read more

FINANCE SITES

wire-30493526-1594136505-669_636x382.jpg

This is Money

Health panel may open lung cancer screening to more smokers


A U.S. health panel wants to widen the number of Americans offered yearly scans for lung cancer by opening the screening to less-heavy smokers. Lung cancer is the nation's top cancer killer, causing more than 135,000 deaths each year. Smoking is the chief cause and quitting the best protection. Usually, lung cancer is diagnosed too late for a good chance at survival. But research shows that annual low-dose CT scans, a type of X-ray, can reduce the risk of death when offered to certain people. In 2013, the U.S.


Read more

saupload_JXan7nBMpAplatEoqk-qiTsCUYC6eHb2C94W9b1f7DCn_szT3hjT4e_yhACTh9xqpmy0IhTT7rAwZPNUY-Qkizd9wMmmROVvvTSKJCLbBuvuHt1R5FifTuRFQjurlrmijGHDDklR.png

Seeking Alpha

Revolution Medicines: A Potential Oncology Niche Disruptor - EXPstocktrader


Followers, take a look at Revolution Medicines (RMVD) as a buying opportunity as the next potential biotech disruptor and under the radar stock with cutting-edge oncology. Let's Take A Look At The Facts Revolution Medicines is a biotech company focused on frontier targets with key signal transduction proteins for which there are: 1) No available direct inhibitors, or 2) The only direct inhibitors may not suppress the full range of ways in which downstream signaling can drive cancer. First, let's look at the company’s pipeline. The company is primarily aiming at the RAS and mTOR pathways, two fundamental signaling networks that have been implicated in a range of aggressive, intractable tumor types.


Read more

og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png

Seeking Alpha

Turning Point Therapeutics inks deal with Zai Lab for lead drug (NASDAQ:TPTX)


Turning Point Therapeutics (TPTX ) signs an agreement with Zai Lab (ZLAB ) for Turning Point’s lead drug candidate, repotrectinib for lung cancer. Under the terms of the agreement, Zai Lab will obtain exclusive rights to develop and promote repotrectinib in Greater China. Turning Point will receive $25M upfront, with potential milestone payments of up to $151M, and royalties Zai Lab anticipates opening additional sites for the TRIDENT-1 Phase 2 registrational study of repotrectinib currently active in 11 countries and enrolling patients with ROS1-positive advanced non-small cell lung cancer and NTRK-positive solid tumors.


Read more

30447356-0-image-a-3_1594043599566.jpg

This is Money

Oncimmune highlights the resurgence of Britain's biotech sector


A resurgence in Britain’s small-cap biotech sector has been one of the few good things to come out of the coronavirus pandemic. As governments have hunted for vaccines, diagnostic tools and treatments, the speed and flexibility of the UK’s smaller biotech constituents has been increasingly recognised, funding for companies become more easily available and the value of the sector has soared. Oncimmune is among those whose share price has risen strongly in the past three months. The AIM-listed company is using its technology to help to analyse the effectiveness of vaccines under development to fight the virus. Oncimmune, though, has more going on than just its COVID19 work and indeed, if anything, the disruption from the virus has been a ...


Read more

ti?nf=Nzk1NTgwMCMzNTg3MDIxIzIwMjU5OTM=

Yahoo Finance

Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19


Approach stimulates immune response by activating B cells to enhance antibody production Safety and scientific basis supported by ongoing cancer clinical trial Study designed to evaluate anti-viral antibody response in up to 30 COVID-19 patients with mild to moderate symptoms Company to host conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT BURLINGAME, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.


Read more

54a3c174275c37caba32b4ba40908533

Yahoo Finance

Respiratory health AI trailblazer VIDA poised for increased scale with newest appointment to leadership team


Todd Johnson joins VIDA, bringing expertise in enterprise imaging, clinical software applications to growing bench of experts for AI-powered pulmonary imaging company CORALVILLE, Iowa, July 7, 2020 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced today that Todd Johnson has joined the company as chief technology officer. Johnson, a leader in enterprise imaging and advanced clinical applications, will apply his expertise to extend the breadth and depth of VIDA's LungPrint® solutions, ensuring the company's AI (artificial intelligence) insights are accessible to a broader base of clinicians to improve the diagnosis and treatment of lung disease.


Read more

c2a1c885e473ef3b54c7ba52ea265792

Yahoo Finance

The Prostate Cancer Foundation Collaboration With Pan-Cancer Consortium Clarifies And Promotes Consistent Use Of Common Terms For Biomarker And Germline Genetic Testing


White Paper Published by Cancer Leaders Provides Industry-Wide Recommendations for Testing Terminology in Precision Medicine LOS ANGELES, July 7, 2020 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially life-saving testing options available for both new cancer diagnoses and progression or recurrence of disease.


Read more

2f89e56f72fa5f84a358dacee2a465aa

Yahoo Finance

JNCCN Study Explores if Insurance is Keeping Pace with Trends in Targeted Cancer Therapy


New research from UCSF and City of Hope examines coverage developments and limitations for liquid biopsy genomic testing in cancer care. PLYMOUTH MEETING, Pa., July 7, 2020 /PRNewswire/ -- New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or "liquid biopsies." CtDNA is formed when tumor cells shed cell-free DNA fragments containing valuable information for detecting the tumor's genetic attributes into the bloodstream.


Read more

0c46b19afbe91028ed34040737f953ce

Yahoo Finance

Hutchinson Regional Medical Center Goes Live with Eon After Record 7-Day Implementation


Hutchinson begins capturing actionable findings for immediate lung cancer impact. DENVER, July 7, 2020 /PRNewswire/ -- Eon, a Denver-based healthtech leader, went live with Hutchinson Regional Medical Center as their lung cancer screening and incidental pulmonary nodule management solution in May 2020. Within the first week, the Kansas-based hospital experienced the positive—and potentially life-saving—benefits of the company's Essential Patient Management (EPM) platform. "The implementation of Eon has made an immediate impact on our patient management workflows.


Read more

72d382d07e63aecd27e34cc9b5886f17

Yahoo Finance

Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing


Improved Communication Is Vital Between Patients and Providers About Testing Needs White Paper Published by Cancer Leaders Provides Industry-Wide Recommendations for Testing Terminology in Precision Medicine WASHINGTON, July 7, 2020 /PRNewswire/ -- A LUNGevity Foundation-led consortium of 41 leading patient advocacy organizations, professional societies, and industry partners has published a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community.


Read more

SOCIAL MEDIA

ProfilePicture.png

Twitter

HemOnc Today : 07/07/2020 15:32:43


🆕 interview with Sarah B. Goldberg, MD @YaleCancer where she discusses results of @TheLancetOncol study indicating that immunotherapy (pembromizulab) shows activity against brain metastases among certain patients with non-small cell lung cancer https://t.co/Z9oBawomvP


Read more

ProfilePicture.png

Twitter

OncLive SOSS OncLiveOnAir: 07/07/2020 16:03:31


In our latest episode of #OncLiveOnAir, @edgardo_ny, of @OncologyFlorida, discusses data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer https://t.co/yBrBeVXAPT


Read more

ProfilePicture.png

Twitter

Gina Columbus : 08/07/2020 00:27:25


Edgardo S. Santos, MD, discusses the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic NSCLC.


Read more